[go: up one dir, main page]

SV1993000080A - Derivados de n4-(oxicarbonil substituidos)-5'-desoxi-5-fluorocitidina ref. ran 4060/166 - Google Patents

Derivados de n4-(oxicarbonil substituidos)-5'-desoxi-5-fluorocitidina ref. ran 4060/166

Info

Publication number
SV1993000080A
SV1993000080A SV1993000080A SV1993000080A SV1993000080A SV 1993000080 A SV1993000080 A SV 1993000080A SV 1993000080 A SV1993000080 A SV 1993000080A SV 1993000080 A SV1993000080 A SV 1993000080A SV 1993000080 A SV1993000080 A SV 1993000080A
Authority
SV
El Salvador
Prior art keywords
radical
fluorocitidine
desoxi
formula
derivatives
Prior art date
Application number
SV1993000080A
Other languages
English (en)
Inventor
Motohiro Arasaki
Hideo Ishitsuka
Isami Kuruma
Masanori Miwa
Chikako Murasaki
Nobuo Schimma
Isao Umeda
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8210304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV1993000080(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SV1993000080A publication Critical patent/SV1993000080A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

LA PRESENTA INVENCIONSE REFIERE A DERIVADOS DE N4-(OXICARBONIL SUBSTITUIDOS)-5¿-DESOXI-5-FLUOROCITIDINA, Y UNA COMPOSICION FARMACEUTICA QUE TIENE LOS MISMOS PARA EL TRATAMIENTO DE TUMORES. MAS PARTICULARMENTE, LA PRESENTE INVENCION SE REFIERE A DERIVADOS DE N4-(OXICARBONIL SUBSTITUIDOS)-5¿-DESOXI-5-FLUOROCITIDINA REPRESENTADOS POR LA FORMULA GENERAL (I)COMPUESTOS PRESENTADOS POR LA FORMULA (I) (VER FORMULA) EN DONDE R1 ES UN RADICAL HIDROCARBURO SATURADO O INSATURADO, LINEAL O RAMIFICADO [EN DONDE EL NUMERO DE ATOMOS DE CARBONO EN LA CADENA LINEAL MAS LARGA DE ESTE RADICAL HIDROCARBURO OSCILA DE TRES A SIETE], O UN RADICAL DE FORLULA -(CH2)N-Y [EN EL CUAL N ES UN NUMERO ENTERO DE 0 A 4, CUANDO Y ES UN RADICAL CICLOHEXILO, O N ES UN NUMERO ENTERO DE 2 A 4 CUANDO Y ES UN RADICAL ALCOXILO INFERIOR DE 1 A 4 ATOMO(S) DE CARBONO O UN RADICAL FENILO],Y R2 ES UN ATOMO DE HIDROGENO O UN RADICAL FACILMENTE HIDROLIZABLE EN CONDICIONES FISIOLOGICAS, ASI COMO LOS HIDRATOS O SOLVATOS DE LOS COMPUESTOS DE FORMULA GENERAL (I),PUEDEN SER UTILIZADOS EN EL TRATAMIENTO DE TUMORES. PUEDEN PREPARASE HACIENDO REACCIONAR UN COMPUESTO DE FORMULA R1-OCOCI CON UNA 5¿-DESOXI-5-FLUOROCITIDINA NO SUBSTITUIDA EN N4 DE LA FORMULA (I) ANTERIOR, EN DONDE R2 REPRESENTA GRUPOS DE PROTECCION, Y SI ES NECESARIO SE ELIMINAN LOS GRUPOS DE PROTECCION.
SV1993000080A 1992-12-18 1993-12-17 Derivados de n4-(oxicarbonil substituidos)-5'-desoxi-5-fluorocitidina ref. ran 4060/166 SV1993000080A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92121538 1992-12-18

Publications (1)

Publication Number Publication Date
SV1993000080A true SV1993000080A (es) 1996-01-26

Family

ID=8210304

Family Applications (1)

Application Number Title Priority Date Filing Date
SV1993000080A SV1993000080A (es) 1992-12-18 1993-12-17 Derivados de n4-(oxicarbonil substituidos)-5'-desoxi-5-fluorocitidina ref. ran 4060/166

Country Status (40)

Country Link
US (1) US5472949A (es)
EP (1) EP0602454B1 (es)
JP (1) JP2501297B2 (es)
KR (1) KR100347218B1 (es)
CN (1) CN1035617C (es)
AT (1) ATE137244T1 (es)
AU (1) AU671491B2 (es)
BG (1) BG61485B1 (es)
BR (1) BR9305089A (es)
CA (1) CA2103324C (es)
CZ (1) CZ284788B6 (es)
DE (1) DE69302360T2 (es)
DK (1) DK0602454T3 (es)
EE (1) EE03086B1 (es)
ES (1) ES2086856T3 (es)
FI (1) FI112365B (es)
GE (1) GEP20074251B (es)
GR (1) GR3020286T3 (es)
HR (1) HRP931430B1 (es)
HU (2) HU218291B (es)
IL (1) IL108000A0 (es)
IS (1) IS4108A (es)
LT (1) LT3115B (es)
LV (1) LV10625B (es)
MY (1) MY109282A (es)
NO (1) NO300066B1 (es)
NZ (1) NZ250414A (es)
PH (1) PH30168A (es)
PL (1) PL174100B1 (es)
RO (1) RO112619B1 (es)
RU (2) RU2458932C2 (es)
SA (1) SA93140409B1 (es)
SI (1) SI9300648B (es)
SK (1) SK281403B6 (es)
SV (1) SV1993000080A (es)
TW (1) TW372239B (es)
UA (1) UA39158C2 (es)
UY (1) UY23697A1 (es)
YU (1) YU49411B (es)
ZA (1) ZA939293B (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476932A (en) * 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
EP0882734B1 (en) * 1997-06-02 2009-08-26 F. Hoffmann-La Roche Ag 5'-Deoxy-cytidine derivatives
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
OA11659A (en) * 1998-09-25 2004-12-08 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
DK1278518T3 (da) * 2000-02-28 2007-01-15 Pfizer Entpr Sarl Synergistisk kombination til behandling af colorektal cancer
WO2001076581A1 (en) * 2000-04-11 2001-10-18 Sayuri Yamada Curcumin compositions
KR100730768B1 (ko) * 2000-08-09 2007-06-21 코오롱생명과학 주식회사 5'-데옥시-ｎ-알킬옥시카르보닐-5-플루오로사이토신-5'-카르복실산 및 그 유도체와 이들의 제조방법
KR100631754B1 (ko) * 2000-08-09 2006-10-09 주식회사 코오롱 Ｎ-알킬옥시카르보닐-5-플루오로사이토신 유도체 및 그의제조방법
GB0113374D0 (en) * 2001-06-04 2001-07-25 Jerram Clare Washing line umbrella
TWI341728B (en) * 2002-01-14 2011-05-11 Novartis Ag Combinations comprising epothilones and anti-metabolites
EP1490090A4 (en) 2002-02-22 2006-09-20 New River Pharmaceuticals Inc SYSTEMS FOR DELIVERING ACTIVE AGENTS AND METHODS FOR PROTECTING AND DELIVERING ACTIVE AGENTS
MXPA05003431A (es) * 2002-11-15 2005-07-05 Warner Lambert Co Quimioterapia de combinacion.
CA2525973A1 (en) * 2003-05-20 2004-12-09 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising capecitabine and a liposomal platinum complex
CA2544320A1 (en) * 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Method of treating cancer using a combination comprising et-743 and 5-fluorouracil
DE602004015331D1 (de) * 2003-12-22 2008-09-04 Hoffmann La Roche Verfahren für fluorcytidinderivate
BRPI0606839B8 (pt) 2005-02-03 2021-12-14 Massachusetts Gen Hospital Uso de uma composição farmacêutica compreendendo um inibidor irreversível de receptor de fator de crescimento epidérmico (egfr)
WO2006103187A2 (en) * 2005-04-01 2006-10-05 F. Hoffmann-La Roche Ag Method for administration of capecitabine
BRPI0613783A2 (pt) 2005-07-18 2011-02-01 Bipar Sciences Inc tratamento de cáncer
ES2384267T3 (es) 2005-07-21 2012-07-03 Nuvo Research Ag Soluciones de clorito estabilizadas en combinación con fluoropirimidinas para el tratamiento del cáncer
RU2451524C2 (ru) 2005-11-04 2012-05-27 Вайет Противоопухолевые комбинации с ингибиторами mtor, герцептином и/или hki-272
SI3184526T1 (sl) 2005-12-13 2019-03-29 Incyte Holdings Corporation Derivati pirolo(2,3-D)pirimidina kot inhibitorji Janus kinaze
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
US20080085310A1 (en) * 2006-10-06 2008-04-10 Maria Oksana Bachynsky Capecitabine rapidly disintegrating tablets
CN100425617C (zh) * 2006-10-31 2008-10-15 浙江海正药业股份有限公司 一种含氟嘧啶类化合物烷氧羰酰化的方法
ITMI20070435A1 (it) 2007-03-05 2008-09-06 Innovate Biotechnology Srl 2',3'-di-o-acil-5-fluoronucleosidi
KR20100015568A (ko) * 2007-04-20 2010-02-12 닥터 레디스 레보러터리즈 리미티드 카페시타빈의 제조 방법
WO2008145403A1 (en) * 2007-06-01 2008-12-04 Synthon B.V. Processes related to making capecitabine
MX2009013402A (es) 2007-06-13 2010-02-24 Incyte Corp Sales de inhibidor de janus cinasa (r)-3-(4-(7h-pirrolo[2,3-d]piri midin-4-il)-1h-pirazol-1-il)-3-ciclopentilpropanitrilo.
US7842675B2 (en) * 2007-09-15 2010-11-30 Protia, Llc Deuterium-enriched capecitabine
WO2009042064A2 (en) 2007-09-21 2009-04-02 Nektar Therapeutics Al, Corporation Oligomer-nucleoside phosphate conjugates
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR101013312B1 (ko) * 2007-11-19 2011-02-09 한미홀딩스 주식회사 카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법
AR064165A1 (es) 2007-12-06 2009-03-18 Richmond Sa Com Ind Y Financie Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
WO2009088989A1 (en) * 2008-01-03 2009-07-16 Plus Chemicals, S.A. Process for the preparation of capecitabine
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
SG191676A1 (en) 2008-06-17 2013-07-31 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
CN109464445A (zh) * 2008-08-04 2019-03-15 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
EP2370414A4 (en) * 2008-12-02 2012-11-14 Reddys Lab Ltd Dr PREPARATION OF CAPECITABINE
WO2010063080A1 (en) * 2008-12-05 2010-06-10 Commonwealth Scientific And Industrial Research Organisation Amphiphile prodrugs
SG174382A1 (en) 2009-04-06 2011-11-28 Wyeth Llc Treatment regimen utilizing neratinib for breast cancer
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
WO2010135621A1 (en) 2009-05-22 2010-11-25 Incyte Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
JP2012533618A (ja) * 2009-07-23 2012-12-27 サイノファーム タイワン リミテッド フルオロシチジン誘導体の製造プロセス
WO2011067588A1 (en) 2009-12-04 2011-06-09 Generics [Uk] Limited Cyclic sulphinyl esters of cytidine
WO2011104540A1 (en) * 2010-02-24 2011-09-01 Generics [Uk] Limited One step process for the preparation of capecitabine
PE20130038A1 (es) 2010-03-10 2013-01-28 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de jak1
JP5917418B2 (ja) 2010-03-12 2016-05-11 ジェンザイム・コーポレーションＧｅｎｚｙｍｅ Ｃｏｒｐｏｒａｔｉｏｎ 乳がんを治療するための併用療法
SG10201503983QA (en) 2010-05-21 2015-06-29 Incyte Corp Topical Formulation for a JAK Inhibitor
CN102260309B (zh) * 2010-05-24 2014-10-22 重庆福安药业(集团)股份有限公司 一种高纯度卡培他滨的制备方法
BR112013012502A2 (pt) 2010-11-19 2019-03-06 Incyte Corporation pirrolopiridina ciclobutil substituída e derivados de pirrolopirimidina derivativos como inibidores de jak
CN102558262A (zh) * 2010-12-23 2012-07-11 天津泰普药品科技发展有限公司 一种高纯度卡培他滨的制备方法
EP2721028B1 (en) 2011-06-20 2015-11-04 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
CN102266303A (zh) * 2011-07-07 2011-12-07 程雪翔 一种卡培他滨药用组合物及其制备方法
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CN102516338B (zh) * 2011-12-09 2014-04-02 海南锦瑞制药股份有限公司 一种卡培他滨化合物、其药物组合物及其制备方法
TWI560195B (en) * 2012-01-13 2016-12-01 Pharmaessentia Corp Novel synthesis of 5-deoxy-5'-fluorocytidine compounds
PL2919766T3 (pl) 2012-11-15 2021-10-04 Incyte Holdings Corporation Postacie dawkowania ruksolitynibu o przedłużonym uwalnianiu
EP3489239B1 (en) 2013-03-06 2021-09-15 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
LT3030227T (lt) 2013-08-07 2020-06-10 Incyte Corporation Prailginto atpalaidavimo jak1 inhibitoriaus dozavimo formos
US20150065447A1 (en) * 2013-08-20 2015-03-05 Incyte Corporation Survival benefit in patients with solid tumors with elevated c-reactive protein levels
EP2883959A1 (en) 2013-12-13 2015-06-17 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
CN103897006A (zh) * 2013-12-18 2014-07-02 吉林修正药业新药开发有限公司 一种卡培他滨异构体的制备方法
WO2015191576A1 (en) 2014-06-09 2015-12-17 Lipomedix Pharmaceuticals Ltd. Combination therapy comprising a liposomal prodrug of mitomycin c and radiotherapy
CN104530164A (zh) * 2014-12-31 2015-04-22 辰欣药业股份有限公司 一种卡培他滨的合成工艺
KR20160117060A (ko) 2015-03-31 2016-10-10 이승주 유아용 탁자
CN105646625B (zh) * 2015-12-29 2019-06-11 江苏吴中医药集团有限公司 一种卡培他滨的制备方法
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
ES2914123T3 (es) 2017-01-09 2022-06-07 Shuttle Pharmaceuticals Inc Inhibidores selectivos de la histona desacetilasa para el tratamiento de una enfermedad humana
TR201702500A2 (tr) * 2017-02-20 2017-07-21 Anadolu Ueniversitesi Serani̇b-2?ni̇n akci̇ğer kanseri̇ ve meme kanseri̇ni̇n tedavi̇si̇nde kullanimi
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
CA3087565A1 (en) 2018-01-09 2019-07-18 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CA3088287A1 (en) 2018-01-10 2019-07-18 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
WO2019143860A1 (en) * 2018-01-19 2019-07-25 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
MX2020007973A (es) 2018-01-30 2020-12-07 Incyte Corp Procesos para preparar (1-(3-fluoro-2-(trifluorometil)isonicotinil )piperidin-4-ona).
SI3773593T1 (sl) 2018-03-30 2024-08-30 Incyte Corporation Zdravljenje hidradenitisa suppurative z zaviralci jak
WO2020144657A1 (en) 2019-01-11 2020-07-16 Lipomedix Pharmaceuticals Ltd. Liposome composition comprising liposomal prodrug of mitomycin c and method of manufacture
AU2020315394A1 (en) 2019-07-17 2022-02-17 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
EP4143199B1 (en) 2020-04-21 2025-11-19 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN116368143A (zh) 2020-08-31 2023-06-30 埃莫里大学 5'-取代的单磷酸核苷、其前药及其相关用途
WO2023177894A1 (en) 2022-03-18 2023-09-21 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and an antimetabolite agent
EP4382093B1 (en) 2022-12-05 2025-08-27 a Fine House S.A. Oral suspensions comprising capecitabine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1135258A (en) * 1979-06-15 1982-11-09 Richard D'souza Process for the preparation of 5'deoxy-5-fluorouridine
ATE92499T1 (de) * 1984-12-04 1993-08-15 Lilly Co Eli Tumorbehandlung bei saeugetieren.
CA1327358C (en) * 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives

Also Published As

Publication number Publication date
IS4108A (is) 1994-06-19
LTIP1627A (en) 1994-07-15
DE69302360T2 (de) 1996-10-31
EP0602454A1 (en) 1994-06-22
TW372239B (en) 1999-10-21
NO300066B1 (no) 1997-04-01
HRP931430A2 (en) 1998-06-30
UA39158C2 (uk) 2001-06-15
FI935616L (fi) 1994-06-19
RU2458932C2 (ru) 2012-08-20
SI9300648A (en) 1994-09-30
EE03086B1 (et) 1998-04-15
ATE137244T1 (de) 1996-05-15
LT3115B (en) 1994-12-27
RU2493162C1 (ru) 2013-09-20
NO934671L (no) 1994-06-20
CN1035617C (zh) 1997-08-13
AU5069093A (en) 1994-06-30
HUT65757A (en) 1994-07-28
RO112619B1 (ro) 1997-11-28
US5472949A (en) 1995-12-05
BG98304A (bg) 1994-01-03
EP0602454B1 (en) 1996-04-24
YU49411B (sh) 2006-01-16
BG61485B1 (bg) 1997-09-30
MY109282A (en) 1996-12-31
CN1094056A (zh) 1994-10-26
CZ284788B6 (cs) 1999-03-17
GR3020286T3 (en) 1996-09-30
ES2086856T3 (es) 1996-07-01
CZ273193A3 (en) 1994-07-13
ZA939293B (en) 1994-06-18
JPH06211891A (ja) 1994-08-02
DK0602454T3 (da) 1996-07-29
JP2501297B2 (ja) 1996-05-29
SI9300648B (sl) 2000-06-30
PL301541A1 (en) 1994-06-27
HU211965A9 (en) 1996-01-29
DE69302360D1 (de) 1996-05-30
CA2103324A1 (en) 1994-06-19
FI112365B (fi) 2003-11-28
AU671491B2 (en) 1996-08-29
CA2103324C (en) 1997-12-23
HU9303525D0 (en) 1994-04-28
SK144493A3 (en) 1994-10-05
BR9305089A (pt) 1994-07-05
GEP20074251B (en) 2007-12-10
HU218291B (en) 2000-07-28
LV10625A (lv) 1995-04-20
HK1005875A1 (en) 1999-01-29
UY23697A1 (es) 1994-06-08
IL108000A0 (en) 1994-04-12
YU77993A (sh) 1996-10-18
SA93140409B1 (ar) 2004-07-24
SK281403B6 (sk) 2001-03-12
FI935616A0 (fi) 1993-12-14
PH30168A (en) 1997-01-21
RU2135511C1 (ru) 1999-08-27
NZ250414A (en) 1995-12-21
HRP931430B1 (en) 1999-08-31
NO934671D0 (no) 1993-12-17
PL174100B1 (pl) 1998-06-30
LV10625B (en) 1996-04-20
KR100347218B1 (ko) 2003-01-24
KR940014428A (ko) 1994-07-18

Similar Documents

Publication Publication Date Title
SV1993000080A (es) Derivados de n4-(oxicarbonil substituidos)-5'-desoxi-5-fluorocitidina ref. ran 4060/166
ATE175958T1 (de) Farnesyl-transferase-inhibitoren, ihre herstellung und sie enthaltende pharmazeutische zusammensetzungen
ES2192031T3 (es) Nuevas amidas aromaticas, su procedimiento de preparacion y su aplicacion como medicamentos.
ECSP066667A (es) Derivados de ciclohexano espirociclicos
ES2174989T3 (es) Pirido(3,2-e)pirazinonas con antiasmatica y procedimiento para su preparacion.
YU18999A (sh) Supstituisani tricikli
KR950031068A (ko) 골다공증의 복합 치료
AR012878A1 (es) Un compuesto derivado de 5'-desoxicitidina, su uso, un proceso para fabricarlo, composiciones farmaceuticas que lo comprende, y un kit que comprende dicha composicion.
BRPI0416474A (pt) uso de um composto, composição, e compostos
MX9305802A (es) Benzoilacetales y cetales yodados.
KR880014002A (ko) 에폭시화합물 및 그를 함유하는 에폭시 수지 조성물
BR9901476A (pt) Polissulfetos de bis (éster hidroxialquil alquìlico).
ES2055804T3 (es) Procedimiento de preparacion de nuevas meta-fenilendiaminas sustituidas con trialcoxi.
MX172211B (es) Composicion de olefina polisulfurada y el procedimiento para su preparacion
ES2133153T3 (es) Nuevos depsipeptidos ciclicos con 18 atomos de anillo, y su empleo para el combate de endoparasitos.
AR004896A1 (es) Derivados de pirazoles acidos, procedimiento de preparación, medicamentos y las composiciones farmacueitcas que los contienen, compuestos para suexclusivo uso en dicho procedimiento y utilizacion de dichos derivados para preparar composiciones farmaceuticas.
ES2123739T3 (es) Nuevos analogos del eburnano, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES476241A1 (es) Procedimiento para la preparacion de derivados de tetraciclonomano.
IT1215587B (it) Derivati della 1-benzoil2-oxo 5-alcossi pirrolidina, loro procedimento di preparazione e loro impiego come sostanza medicinale.
MX9304313A (es) Nuevos derivados de acido difosfonico, que contienen grupos amidina aciclicos, procedimiento para supreparacion y composiciones farmaceuticas que los contienen.
ES2078723T3 (es) 3-acilamino-2-pirrolidinonas como potenciadores de los procesos de aprendizaje y de la memoria y composiciones farmaceuticas que las contienen.
ES2082232T3 (es) Derivados de pirrolidina diona.
AR041317A1 (es) Tratamiento pesticida de productos alimenticios almacenados, camaras,estructuras y obras de arte, con compuestos de azufre
BR0200688A (pt) Composições de borracha contendo oligÈmeros acoplados por silìcio
PE20030769A1 (es) Compuestos de 1,5-diaminopentano-3-ol sustituidos, procedimientos para su preparacion, medicamentos que contienen este compuesto y el uso de estos compuestos para la preparacion de medicamentos

Legal Events

Date Code Title Description
FD Lapse
FD Lapse
FD Lapse